P-CHOP: Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma: A Single-Institution Phase II Study

Giorgio Cocconi, Vittorio Franciosi, Anna Dodero, Alessandra Bologna, Giovanna Vasini, Vincenzo De Lisi, Beatrice Di Blasio, Guido Ceci, Roberta Camisa, Stefano Cascinu

Research output: Contribution to journalArticle

Abstract

We designed the P-CHOP regimen, which involves the addition of cisplatin (P) to the standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, and investigated its activity and its toxicities in a single institution phase II study. Twenty-two consecutive patients with untreated, aggressive, stage I-IV non-Hodgkin lymphoma were enrolled in the study. Cisplatin was administered at a dose of 40 mg/m2 on days 1 and 2, every 3 weeks; the dose and schedule of the other agents were identical to those used in the standard CHOP regimen. The complete remission (CR) rate was 86% in eligible and 80% in all the treated patients, which compares favorably with the CR rates of two recent randomized studies of CHOP versus other regimens. P-CHOP is an innovative regimen for the front-line treatment of aggressive non-Hodgkin lymphoma. It is feasible and warrants further research, which would ideally take the form of a randomized comparison of P-CHOP and CHOP, possibly with the addition of rituximab in both arms.

Original languageEnglish
Pages (from-to)535-542
Number of pages8
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume26
Issue number6
DOIs
Publication statusPublished - Dec 2003

Keywords

  • Aggressive non-Hodgkin lymphoma
  • Cisplatin
  • First-line chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'P-CHOP: Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma: A Single-Institution Phase II Study'. Together they form a unique fingerprint.

Cite this